<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Martinez-Balsalobre E</submitter><funding>Ministry of Science and Innovation. Spain</funding><funding>Ministry of Economy and Competitiveness | Instituto de Salud Carlos III</funding><funding>Fundación Ramón Areces Consejeria de Sanidad de la Región de Murcia. ZEBER</funding><pagination>5912</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10516865</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(1)</volume><pubmed_abstract>Telomerase RNA (TERC) has a noncanonical function in myelopoiesis binding to a consensus DNA binding sequence and attracting RNA polymerase II (RNA Pol II), thus facilitating myeloid gene expression. The CR4/CR5 domain of TERC is known to play this role, since a mutation of this domain found in dyskeratosis congenita (DC) patients decreases its affinity for RNA Pol II, impairing its myelopoietic activity as a result. In this study, we report that two aptamers, short single-stranded oligonucleotides, based on the CR4/CR5 domain were able to increase myelopoiesis without affecting erythropoiesis in zebrafish. Mechanistically, the aptamers functioned as full terc; that is, they increased the expression of master myeloid genes, independently of endogenous terc, by interacting with RNA Pol II a</pubmed_abstract><journal>Nature communications</journal><pubmed_title>Telomerase RNA-based aptamers restore defective myelopoiesis in congenital neutropenic syndromes.</pubmed_title><pmcid>PMC10516865</pmcid><funding_grant_id>PI19/00188</funding_grant_id><funding_grant_id>PI22/00861</funding_grant_id><pubmed_authors>Garcia-Moreno D</pubmed_authors><pubmed_authors>Garcia-Castillo J</pubmed_authors><pubmed_authors>Mulero V</pubmed_authors><pubmed_authors>Naranjo-Sanchez E</pubmed_authors><pubmed_authors>Cayuela ML</pubmed_authors><pubmed_authors>Fernandez-Lajarin M</pubmed_authors><pubmed_authors>Alcaraz-Perez F</pubmed_authors><pubmed_authors>Martinez-Balsalobre E</pubmed_authors><pubmed_authors>Blasco MA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Telomerase RNA-based aptamers restore defective myelopoiesis in congenital neutropenic syndromes.</name><description>Telomerase RNA (TERC) has a noncanonical function in myelopoiesis binding to a consensus DNA binding sequence and attracting RNA polymerase II (RNA Pol II), thus facilitating myeloid gene expression. The CR4/CR5 domain of TERC is known to play this role, since a mutation of this domain found in dyskeratosis congenita (DC) patients decreases its affinity for RNA Pol II, impairing its myelopoietic activity as a result. In this study, we report that two aptamers, short single-stranded oligonucleotides, based on the CR4/CR5 domain were able to increase myelopoiesis without affecting erythropoiesis in zebrafish. Mechanistically, the aptamers functioned as full terc; that is, they increased the expression of master myeloid genes, independently of endogenous terc, by interacting with RNA Pol II a</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Sep</publication><modification>2026-06-04T06:33:00.344Z</modification><creation>2024-11-15T17:13:05.88Z</creation></dates><accession>S-EPMC10516865</accession><cross_references><pubmed>37737237</pubmed><doi>10.1038/s41467-023-41472-7</doi></cross_references></HashMap>